Nadia Solovieff
Harvard University
H-index: 29
North America-United States
Top articles of Nadia Solovieff
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA … | Clinical Cancer Research | Aleix Prat Nadia Solovieff Fabrice André Joyce O'Shaughnessy David A Cameron | 2024/2/16 |
Methodology for Good Machine Learning with Multi‐Omics Data | Clinical Pharmacology & Therapeutics | Thibaud Coroller Berkman Sahiner Anup Amatya Alexej Gossmann Konstantinos Karagiannis | 2024/4 |
Multi-omics investigation on the prognostic and predictive factors in metastatic breast cancer using data from Phase III ribociclib clinical trials: A statistical and machine … | medRxiv | Thibaud P Coroller Berkman Sahiner Anup Amatya Alexej Gossman Konstantinos Karagiannis | 2023 |
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials | Annals of Oncology | Fabrice Andre Fei Su Nadia Solovieff G Hortobagyi S Chia | 2023/11/1 |
Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing | Science translational medicine | Lauren Fairchild Jeanne Whalen Katie D’Aco Jincheng Wu Carroll B Gustafson | 2023/3/29 |
Abstract PD17-08: Pooled gene expression analysis and association with treatment response in patients with HR+/HER2− advanced breast cancer in the MONALEESA-2,-3, and-7 trials | Cancer Research | Aditya Bardia Faye Su Nadia Solovieff Fabrice Andre Carlos Arteaga | 2023/3/1 |
Abstract P5-02-14: Identification of mechanisms of acquired resistance to ribociclib plus endocrine therapy using baseline and end-of-treatment circulating tumor DNA samples in … | Cancer Research | Fabrice Andre Nadia Solovieff Faye Su Aditya Bardia Patrick Neven | 2023/3/1 |
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced … | Clinical Cancer Research | Yen-Shen Lu Seock-Ah Im Marco Colleoni Fabio Franke Aditya Bardia | 2022/3/1 |
Abstract GS2-00: correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2,-3, and-7 studies of ribociclib+ endocrine therapy in patients with HR+ … | Cancer Research | Lisa Carey Nadia Solovieff Fabrice André Joyce O'Shaughnessy David A Cameron | 2022/2/15 |
Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies | Cancer Research | Dejan Juric Chong Ma Ralph Tiedt Yoon-Sim Yap Joanne Chiu | 2022/2/15 |
Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2-advanced breast cancer (ABC) across the MONALEESA (ML) studies | Cancer Research | Aleix Prat Nadia Solovieff Faye Su Aditya Bardia Patrick Neven | 2022/2/15 |
Clonal hematopoiesis detection in cancer patients using cell free DNA sequencing | bioRxiv | Lauren Fairchild Jeanne Whalen Katie D’Aco Jincheng Wu Carroll B Gustafson | 2021/10/29 |
1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma | Annals of Oncology | C Robert D Schadendorf GV Long P Ascierto S Intagliata | 2021/9/1 |
Genomic profiling of premenopausal HR+ and HER2–metastatic breast cancer by circulating tumor DNA and association of genetic alterations with therapeutic response to endocrine … | JCO precision oncology | Aditya Bardia Fei Su Nadia Solovieff Seock-Ah Im Joohyuk Sohn | 2021/8 |
Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA phase III studies | Journal of Clinical Oncology | Aleix Prat Anwesha Chaudhury Nadia Solovieff Laia Paré Débora Martinez | 2021/5/5 |
Upregulation of Immune Response Biomarkers by Ribociclib Plus Endocrine Therapy in Paired Tumor Samples From Phase I Studies | San Antonio Breast Cancer Symposium 2021 | Dejan Juric Chong Ma Ralph Tiedt Yoon-Sim Yap WYJ Chiu | 2021 |
